Recently, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have emerged as a new class of drugs designed to treat patients with type 2 diabetes (T2D), but have also been shown to be protective against HF-related events and CV mortality
At our clinic, patients who come in with chronic GI inflammation, SIBO residuals, or a history of NSAID-induced gastritis are the group most likely to report subjective improvement on BPC-157 within the first 30 days
OomenAGBleekerEABosPMVan BroekhuizenFGottardoSGroenewoldMet al
Outsourced vendors source finished peptides from third-party manufacturers, apply their own QC and labeling, and then resell them
Post-workout protein intake drives muscle protein synthesis and offsets training-induced breakdown
S., Madhivanan, K., Atchudan, R., Arya, S